The development of subtype-selective ligands to inhibit voltage-sensitive sodium channels (VSSCs) has been attempted with the aim of developing therapeutic compounds. Tetrodotoxin (TTX) is a toxin from pufferfish that strongly inhibits VSSCs. Many TTX analogues have been identified from marine and terrestrial sources, although their specificity for particular VSSC subtypes has not been investigated. Herein, we describe the binding of 11 TTX analogues to human VSSC subtypes Na v 1.1-Na v 1.7.
Introduction
Voltage-sensitive sodium channels (VSSCs) are composed of a pore-forming α-subunit and auxiliary β-subunits . The primary group of the α-subunit is classified into Na v 1.1 to Na v 1.9 subgroups , which play various physiological roles in different organs and are potentially responsible for genetic diseases, chronic pain, epilepsy and cardiac dysrhythmia (Tan et al., 2001; Antzelevitch et al., 2005; Meisler and Kearney, 2005; Amir et al., 2006) . Various models for VSSCs have been constructed; however, a mammalian VSSC has yet to be crystalized. Therefore, patch-clamp studies, binding assays and photoaffinity-labelling experiments, which utilize naturally occurring toxins and synthetic compounds that modulate VSSCs, have been important for the understanding of the structures and functions of mammalian VSSCs and to develop improved therapies.
Naturally occurring toxins that bind to VSSCs are classified into six groups based on their binding sites (Sites 1 to 6) (Catterall et al., 2007) . However, most of these natural toxins do not recognize a specific subtype of VSSCs and are not applicable for clinical use. Local anaesthetics, anticonvulsants and antiarrhythmic drugs are not natural toxins but are known to block VSSCs; although they are used clinically, they have unavoidable side effects (Bagal et al., 2014) . Thus, despite the high sequence identity between different VSSC subtypes, subtype-specific inhibitors have been targeted for drug development. Site 1 is located at the entrance of the pore overlapping the ion selectivity filter. Here, tetrodotoxin (TTX, 1, Figure 1 ), saxitoxin (STX) and μ-conotoxin block the sodium current by occluding the ion permeation pathway (Narahashi et al., 1964; 1967; Ohizumi et al., 1986) . The molecular determinants of the high affinity binding of TTX (1) to VSSCs have been investigated using various TTX analogues in binding assays with rat brain synaptosomes (Yotsu-Yamashita et al., 1999) , or cell-based assays using the neuroblastoma cell line Neuro 2A (YotsuYamashita et al., 2003; Kudo et al., 2014; Saruhashi et al., 2016) . However, rat brain synaptosomes and mouse neuroblastoma Neuro 2A cells express multiple subtypes of VSSCs (Lou et al., 2005) . The molecular determinants of VSSCs that generate high affinity binding to TTX (1) were also demonstrated by VSSC mutants, mostly those of Na v 1.2 and Na v 1.4 (Terlau et al., 1991; Choudhary et al., 2003) . TTX (1) and its various analogues have been identified in many marine and terrestrial species (Yotsu-Yamashita, 2001 ). With subtle modifications of the TTX (1) structure, we believe that a TTX analogue would exhibit subtype selectivity.
Therefore, we expressed human VSSCs (Na v 1.1-Na v 1.7) in HEK293T cells and evaluated the ability of TTX analogues (1-12, Figure 1 ) to block each subtype using whole-cell patch-clamp recordings. Chiriquitoxin (CHTX, 2) exclusively exhibited less binding to Na v 1.7 than to the other TTXsensitive subtypes. Molecular determinants for the specific reduction of CHTX (2) blockade against Na v 1.7 were deduced to be Met 1425 and Asp 1426 in domain III of the VSSC.
Figure 1
The structures of TTX and its analogues: TTX (1), CHTX (2), 8-deoxyTTX (3), 4,9-anhydroTTX (4), 4,9-anhydroCHTX (5), 4,9-anhydro-8-deoxyTTX (6), 5-deoxyTTX (7), 5, 5, 6, , 4,9-anhydro-5-deoxyTTX (10), 4,9-anhydro-5,11-dideoxyTTX (11) and 4,9-anhydro-5,6,11-trideoxyTTX (12) are shown.
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We discuss the spatial location of the CHTX (2) based on VSSC models reported in the literature.
Methods
Preparation of the plasmid DNA for VSSC subtype expression
The cDNA for each sodium channel subtype was obtained from Origene Technologies (Rockville, MD, USA). Plasmids expressing each VSSC subtype in HEK293T cells, including pCDM8 Na v 1.2, pCDM8 Na v 1.4, pCDM8 Na v 1.5, pCDM8 Na v 1.6 and pCDM8 Na v 1.7, were constructed as follows.
First, the open reading frames (ORF) of Na v 1.2, Na v 1.4, Na v 1.5, Na v 1.6 and Na v 1.7 were amplified by PCR using the forward and reverse primers AGG GAG ACC CAA GCT GAA TTC GTC GAC TGG ATC CGG and TGG AAG ATC CCT CGA GCC GGC CGT TTA AAC CTT ATC, respectively, with KOD-plus as the polymerase. The reaction mixture was subjected to PCR conditions of 94°C for 2 min, followed by 30 cycles of 98°C for 10 s, 60°C for 30 s and 68°C for 3 min. Using the same PCR conditions, linearized pCDM8 was amplified using pCDM8 as the template and forward and reverse primers of CTC GAG GGA TCT TCC and AAG CTT GGG TCT CCC respectively. The amplified ORF and linearized vector were subjected to the In-Fusion HD Cloning kit to obtain the desired vector. Next, pCDM8 Na v 1.1 and pCDM8 Na v 1.3 were constructed in a conventional manner. PCR was conducted with the cDNA purchased from Origene Technologies, Inc. as the template. The forward primer ATCT CTC GAG GAA TTC GTC GAC TGG and reverse primers AAC TAT GCG GCC GCG TTA TTT CCC TTT GGC (for Na v 1.1) and GGC TAT GCG GCC GCG TTA CTT TTG ATT TTC (for Na v 1.3) were designed. The PCR product and pCDM8 were both cut with XhoI and NotI and ligated to each other with T4 DNA ligase. The plasmid pCDM8 Na v 1.7 T1425M was constructed as follows. The forward and reverse primers for generating T1425M were CCG TAG CTA AGG GAT GGA TGA T and GTC GCC CAT AAT AAT CAT CCA TCC respectively. For the first step in generating T1425M, PCR was performed using two pairs of primers, ATC TCT CGA GGA ATT CGT CGA CTG G and GTC GCC CAT AAT AAT CAT CCA TCC, as well as CCG TAG CTA AGG GAT GGA TGA T and GGC TAT GCG GCC GCG TTA TTT TTT GCT TTC, with pCDM8 Na v 1.7 as the template. The PCR conditions were 94°C for 3 min, followed by 40 cycles of 98°C for 10 s, 60°C for 30 s and 68°C for 3 min. The two amplified fragments were used as the templates, and a second cycle of PCR was performed using the same conditions with another pair of primers, ATCT CTC GAG GAA TTC GTC GAC TGG and GGC TAT GCG GCC GCG TTA TTT TTT GCT TTC. The PCR product and pCDM8 were both cut with XhoI and NotI and ligated to each other with T4 DNA ligase. After ligation, in all cases, competent TOP10/P3 cells were used to recruit a single plasmid DNA, and the pCDM8 plasmid was extracted with the Viogene Midi Plus Purification System (Viogene BioTek Corp., Sijhih Dist., New Taipei City, Taiwan). The plasmid was analysed at Fasmac Co., Ltd. to obtain confirmation of the sequences.
The plasmid pCDM8 Na v 1.7 I1426D was constructed as follows. The forward and reverse primers for generating I1426D were CCT ATA CGG ATG GAC GGA CAT T and CCT ATA CGG ATG GAC GGA CAT T respectively. For the first step in generating I1426D, PCR was performed using two pairs of primers, ATCT CTC GAG GAA TTC GTC GAC TGG and CCT ATA CGG ATG GAC GGA CAT T as well as CCT ATA CGG ATG GAC GGA CAT T and GGC TAT GCG GCC GCG TTA TTT TTT GCT TTC, using pCDM8 Na v 1.7 as the template. The subsequent procedures, including the PCR conditions, digestion with restriction enzymes, ligation, cloning and sequencing, were identical to those used for the construction of pCDM8 Na v 1.7 T1425M.
Expression of each VSSC subtype in HEK293T cells
HEK293T cells were maintained in minimum essential medium (MEM) containing 10 U·mL À1 penicillin, 10 μg·mL À1 streptomycin (Thermo Fischer Scientific K. K., Yokohama, Kanagawa, Japan) and 10% v . v À1 FBS. HEK293T cells at 40-50% confluency were co-transfected using a calcium phosphate method (Chen and Okayama, 1987) , with the pCDM8 plasmid carrying the cDNA of the VSSC and EBO pCD Leu2 (ATC 59565) carrying the cDNA of the CD8 antigen. After 8-12 h, the cells were treated with 0.05% EDTA (Thermo Fischer Scientific K. K., Yokohama, Kanagawa, Japan) to obtain single cells in a 35 mm dish for whole-cell patch-clamp recordings. VSSC expression in the transfected cells was detected with anti-CD8 conjugated magnetic beads (Dynabeads CD8, Thermo Fischer Scientific K. K., Yokohama, Kanagawa, Japan). We originally planned to heterologously express Na v 1.8 and Na v 1.9 in the ND7/23 cell line, which was generated from mouse neuroblastoma and rat dorsal root ganglion neurons. However, an endogenous sodium current in ND7/23 cells was observed upon depolarization, which was inappropriate for the present study.
Patch-clamp recordings
Patch-clamp recordings were conducted using a whole-cell recording configuration. The extracellular buffer comprised 140 mM NaCl, 1.0 mM MgCl 2 ·6H 2 O, 5.0 mM CsCl, 1.8 mM CaCl 2 and 10 mM HEPES (pH 7.4, adjusted with NaOH). The intracellular buffer contained 189 mM N-methyl-Dglucamine, 1.0 mM NaCl, 4.0 mM MgCl 2 , 0.1 mM 1,2-bis(2-aminophenoxy)ethane-N,N,N 0 ,N 0 -tetraacetic acid, 25 mM tris-phosphocreatine, 2.0 mM ATP disodium salt, 0.2 mM GTP monosodium salt, and 40 mM HEPES (pH 7.4, adjusted with CsOH) (Bricelj et al., 2005) . Recordings were performed at room temperature using an EPC10 USB amplifier (HEKA Elektronik Dr. Schulze GmbH, Lambrecht, Pfalz, Germany) that was controlled using Patchmaster software. When a glass capillary was attached to the bath solution, the capillary resistance was 2-5 MΩ. The series resistance was compensated at more than 50%. Experimental investigations into the activities of TTX and its analogues were conducted as long as the 'gigaseal' was retained.
Data analysis
The whole-cell patch-clamp experiments were analysed using IgorPro software. Steady-state activation was analysed according to the following protocol. The holding potential was set at À100 mV, and a series of rectangular pulses consisting of À100 mV for 10 ms, test potential in the range À80 to +40 mV in 10 mV increments for 20 ms and À100 mV for 10 ms were applied to the cell every 5 s to obtain an I-V relationship. Linear fitting of this I-V curve between 0 and 40 mV was performed to calculate the V-intercept, which is the reversal potential of V rev . Conductance was calculated at each membrane potential using the Boltzmann equation: G = I peak /(V À V rev ), where G, I peak , V and V rev represent the conductance, peak sodium current, membrane potential and reversal potential respectively. G was divided by the maximum conductance to obtain the normalized conductance, G n (V), which was plotted against the membrane potential (V) and fitted to the Boltzmann equation in the following form:
, where G n (V), V, V a and S represent the normalized conductance, the membrane potential, half-activation potential and the slope factor respectively. Steady-state inactivation was also analysed using a double-pulse protocol as follows. The holding potential was set at À100 mV, and a series of rectangular pulses consisting of À100 mV for 10 ms, the test potential ranging from À120 to 0 mV in 10 ms increments for 100 ms, À100 mV for 1 ms, À10 mV for 50 ms and À100 mV for 10 ms were applied to the cell every 5 s. The peak sodium current induced by the test pulse at À10 mV in the fourth step was normalized to the maximum sodium current observed. The normalized current, I h (V), was plotted against the 100 ms conditioning pulse in the second step. I h (V) was fitted as a function of
, where I h (V), V, V i and S represent the normalized current, membrane potential, half-inactivation potential and slope factor respectively.
The dose-dependent inhibition of the expressed VSSC by the test compound was investigated as follows. Test pulses to À10 mV for 20 ms were applied to the cell every 5 s. Extracellular buffer containing the test compound was applied to the cell by a Y-tube system (Yamaoka et al., 2004) , and the effect was evaluated by means of a decrease in the peak current. Experimental data with a run-down effect of less than 15% were chosen, and the inhibitory effect of the test compound was compensated against the run-down effect. The inhibition ratio (%) was plotted against the concentration of the test compound, and the dose-response curve was fitted to the
, where R (L), R min , R max , L and rate represent the inhibition ratio at a concentration of the test compound, maximum inhibition ratio, minimum inhibition ratio, concentration of the test compound and Hill coefficient respectively. The use-dependent block of the expressed VSSC by the test compound was investigated using the following procedure. The cell was subjected to a series of 2 ms depolarization pulses from a holding potential of À100 mV to the test potential of À10 mV, with frequencies of 1 Hz for 5 s, 2 Hz for 5 s, 5 Hz for 5 s and 10 Hz for 5 s. The test compound with extracellular buffer was applied to the cell by a Y-tube system (Yamaoka et al., 2004) , and the effect was evaluated by means of a decrease in the peak current.
Compliance with design and statistical analysis requirements
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Group sizes. A priori power analysis and post hoc tests were performed with G'power (Faul et al., 2007) to determine and confirm the size of treatments. For a priori power analysis, α error probability, power and effect size were 0.05, 0.8 and 0.5 respectively. The limited quantities of synthetic samples did not permit all group sizes to be greater than five. However, the data subjected to statistical analysis were derived from more than five experiments in each group.
Randomization and blinding. Randomization and blinding were not performed as they are not standard procedures in whole-cell patch-clamp recording. Instead, to improve the transparency of the study, one person designed and wrote the pulse protocols for the whole-cell patch-clamp recordings, four different persons conducted the whole-cell patch-clamp recordings and two persons independently analysed the experimental data. Extracellular buffers containing the test compound at various concentrations were prepared on the day of experiment.
Statistical comparison.
Group mean values and statistical analyses used independent values. When comparing any two groups, the threshold for statistical significance was defined as P = 0.05 and was kept constant in the present study. After ANOVA, a post hoc test was performed only if F was statistically significant (P < 0.05).
Translation. This study is a basic research study and is not subject to clinical relevance.
Materials
TTX (1) (Ohyabu et al., 2003; Nishikawa et al., 2004; Urabe et al., 2006) , CHTX (2) (Adachi et al., 2014a) , 8-deoxyTTX (3) (Satake et al., 2014) , 4,9-anhydroTTX (4) (Ohyabu et al., 2003; Nishikawa et al., 2004; Urabe et al., 2006) , 4,9-anhydroCHTX (5), 4,9-anhydro-8-deoxyTTX (6), 5-deoxyTTX (7) (Satake et al., 2014), 5,11-dideoxyTTX (8) (Nishikawa et al., 1999; Asai et al., 2001; Yotsu-Yamashita et al., 2013), 5,6,11-trideoxyTTX (9) (Adachi et al., 2014b) , 4,9-anhydro-5-deoxyTTX (10) (Satake et al., 2014) , 4,9-anhydro-5,11-dideoxyTTX (11) (Nishikawa et al., 1999; Asai et al., 2001; Yotsu-Yamashita et al., 2013) and 4,9-anhydro-5,6,11-trideoxyTTX (12) (Adachi et al., 2014b) were synthesized as reported in the literature (Figure 1 KOD-Plus, T4 ligase and the In-Fusion HD Cloning kit were purchased from Takara Bio, Inc. (Kusatsu, Shiga, Japan). PCR primers were purchased from Fasmac Co., Ltd. (Atsugi, Kanagawa, Japan). Competent TOP10/P3 cells and the restriction enzymes HindIII, XhoI and NotI were purchased from Thermo Fischer Scientific (Thermo Fischer Scientific K. K., Yokohama, Kanagawa, Japan). Bacto agar, bacto tryptone and bacto yeast extract were purchased from Becton, Dickinson and Company (Franklin Lakes, New Jersey, USA). All other chemicals were purchased from Nacalai Tesque, Inc. (Nakagyo, Kyoto, Japan); Wako Pure Chemical Industries, Ltd. (Chuou, Osaka, Japan); or Sigma-Aldrich Japan, Inc. (Shinagawa, Tokyo, Japan).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOL-OGY 2015/16 .
Results

Inhibition of the VSSC subtypes by TTX and its analogues
Whole-cell patch-clamp recordings were conducted to confirm the expression of each VSSC, and the steady-state activation (Supporting Information Figure S1 ) and inactivation (Supporting Information Figure S2 ) of the channels were subsequently analysed (Supporting Information Figure S3 ). The half-activation potentials (Supporting Information Figure S3A ) and half-inactivation potentials (Supporting Information Figure S3B ) were identical, within error, to the reported values (Supporting Information Figure S3C ) .
First, the inhibitory activity of TTX (1) was evaluated ( Figure 2 ). The peak sodium currents of Na v 1.1 (Figure 2A ), Na v 1.2 ( Figure 2B ), Na v 1.3 ( Figure 2C ), Na v 1.4 ( Figure 2D ), Na v 1.6 ( Figure 2F ) and Na v 1.7 ( Figure 2G ) were inhibited by Figure 2 Inhibitory effects of TTX (1) on Na v 1.1-Na v 1.7 expressed in HEK293T cells. The sodium currents in (A) Na v 1.1, (B) Na v 1.2, (C) Na v 1.3, (D) Na v 1.4, (E) Na v 1.5, (F) Na v 1.6 and (G) Na v 1.7 were recorded in the absence (black line) and presence (red line) of TTX (1). The TTX concentration was 10 nM in (AÀD, F, G) and 30 nM in (E). (H) The dose-dependent inhibitory effects of TTX (1) on Na v 1.1, Na v 1.2, Na v 1.3, Na v 1.4, Na v 1.5, Na v 1.6 and Na v 1.7 are shown.
72 ± 2% (n = 4), 36 ± 4% (n = 3), 67 ± 4% (n = 8), 53 ± 3% (n = 3), 74 ± 2% (n = 3) and 25 ± 7% (n = 6), respectively, in the presence of 10 nM TTX (1). By contrast, Na v 1.5 ( Figure 2E ) was insensitive to TTX (1), with a 6.9 ± 2.0% block at 30 nM because of the lack of an aromatic amino acid residue at the TTX binding site in Na v 1.5 (Satin et al., 1992) . The blocking activity was reversible. When the cell was perfused with TTX-free extracellular buffer, the Na v 1.1ÀNa v 1.7 sodium currents were restored to levels observed for the control. Other TTX analogues (2-12) tested in the present study exhibited reversible binding similar to that of TTX (1). The dose response of TTX (1) against Na v 1.1ÀNav1.7 was investigated, and the IC 50 value was determined by fitting the dose-response curve to the Hill equation ( Figure 2H ). The IC 50 values shown in Table 1 , in addition to the parameters for steady-state activation and inactivation (Supporting Information Figure S3C ), indicated the successful establishment of the assay system. Next, the TTX analogues (3-12) were evaluated for their inhibitory effects on the Na v subtypes. When these analogues were tested at a maximum concentration of 300 nM, the channels were largely insensitive to 8-deoxyTTX (3), 5-deoxyTTX (7), 5,11-dideoxyTTX (8) and 5,6,11-trideoxyTTX (9) with less than 10% inhibition (Supporting Information Table S1 ). 8-DeoxyTTX (3) was tested at a higher concentration against Na v 1.1, Na v 1.3, Na v 1.4 and Na v 1.6, while 5-deoxyTTX (7) was tested at a higher concentration against Na v 1.1, Na v 1.3 and Na v 1.4 (Table 1 ). The IC 50 value of either of the two compounds for each subtype of VSSC was approximately three orders of magnitude larger than that of TTX (1). Rosker et al. (2007) showed that 4,9-anhydroTTX (4) selectively inhibits Na v 1.6 with an IC 50 value of 7.8 ± 2.3 nM but does not affect other subtypes. Teramoto et al. revealed the inhibition of a resurgent-like current through Na v 1.6 expressed in mouse vas deferens myocytes (Teramoto et al., 2012; Teramoto and Yotsu-Yamashita, 2015) . We attempted to reproduce the remarkable activity of 4,9-anhydroTTX (4) and administered the compound to Na v 1.6, as well as TTX-sensitive Na v 1.4 and TTX-resistant Na v 1.5 for comparison. However, we observed that 300 nM 4,9-anhydroTTX (4) inhibited 51 ± 10% of Na v 1.6 (Supporting Information Table S1 ), and the IC 50 value was 294 ± 25 nM ( Table 1 ). The sodium currents for Na v 1.4 and Na v 1.5 were also reduced by 3.4 ± 0.2% and 3.1 ± 0.8% (n = 3), respectively (Supporting Information Table S1 ). In addition, no other 4,9-anhydrotype analogues (5, 6 and 10-12) inhibited Na v 1.4 and Na v 1.5 ( Table 1) .
Inhibition of VSSC subtypes by chiriquitoxin and reduced binding of chiriquitoxin to Na v 1.7
CHTX (2) is a TTX analogue with a glycine functionality connected to C11 (Kao et al., 1981; Yotsu et al., 1990) that is known to inhibit both voltage-sensitive potassium channels and sodium channels (Kao et al., 1981; Yang and Kao, 1992) . Our study presents the first investigation of CHTX (2) subtype selectivity. The initial screening of Na v 1.1ÀNa v 1.7 was conducted using 30 nM CHTX (2), which was found to inhibit Na v 1.1 ( Figure 3A) , Na v 1.2 ( Figure 3B ), Na v 1.3 ( Figure 3C ), Na v 1.4 ( Figure 3D ) and Na v 1.6 Table 1 The IC 50 concentration or the maximum concentrations of compounds (1-12) against Na v 1.1-Na v 1.7
Compound Na v 1.1 Na v 1.2 Na v 1.3 Na v 1.4 Na v 1.5 Na v 1.6 Na v 1.7
TTX (1) 4.1 ± 0.2 nM (n = 4) 14 ± 2 nM (n = 3)
5.3 ± 0.6 nM (n = 5) 7.6 ± 2.6 nM (n = 3)
2.3 ± 0.0 nM (n = 3) 36 ± 7 nM (n = 5) CHTX (2) 26 ± 1 nM (n = 5) 27 ± 7 nM (n = 3) 14 ± 2 nM (n = 7) 50 ± 3 nM (n = 3)
1.9 ± 0.9 μM (n = 4) 43 ± 10 nM (n = 4) 471 ± 27 nM (n = 7)
8-deoxyTTX (3) 4.8 ± 0.46 μM (n = 3) >300 nM 4.9 ± 0.4 μM (n = 3)
,11-trideoxyTTX (9) >300 nM >300 nM >300 nM >300 nM >300 nM >300 nM >300 nM 4,9-anhydro-5-deoxyTTX (10) ND ND ND >100 nM >100 nM ND ND 4,9-anhydro-5,11-dideoxyTTX (11) ND ND ND >100 nM >100 nM ND ND 4,9-anhydro-5,6,11-trideoxyTTX (12) ND ND ND >100 nM >100 nM ND ND
The IC 50 concentrations for TTX (1), CHTX (2), 8-deoxyTTX (3) and 5-deoxyTTX (7) are presented as the means ± SEM. The number of experiments is indicated in parentheses below the IC 50 values. VSSC subtypes that were not tested for inhibitory activity of the test compound are marked as ND.
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( Figure 3F ) by 52 ± 3% (n = 5), 63 ± 8% (n = 3), 72 ± 3% (n = 9), 40 ± 6% (n = 3), 33 ± 4% (n = 4) and 7.9 ± 2.2% (n = 10) respectively (n = 3), whereas for Na v 1.5, 5.3 ± 1.0% inhibition (n = 3) was observed for 100 nM CHTX (2) ( Figure 3E ). The dose-response relationship was deduced for CHTX (2) and Na v 1.1ÀNa v 1.7; their IC 50 values were 2-19-fold greater than those for TTX (1 , Table 1 ). However, it should be noted that Na v 1.7 was approximately 34-fold less sensitive to CHTX (2) than Na v 1.3 (P < 0.05, Table 1 ). Alignment of the amino acid residues for the TTX binding sites from domain I to domain IV was performed to determine the molecular determinants that generated the reduced binding of CHTX (2) to Na v 1.7. As shown in Figure 4A , most of the amino acid sequences of the TTX binding sites were highly conserved from Na v 1.1 to Na v 1. were mutated to Met and Asp, respectively, and the inhibitory effect of CHTX (2) on the mutant was evaluated ( Figure 4B ). CHTX (2) inhibited Na v 1.7 T1425M and Na v 1.7 I1426D with IC 50 values of 30 ± 2 nM (n = 7, P < 0.05, significantly different from Na v 1.7) and 94 ± 18 nM (n = 7, P < 0.05, significantly different from Na v 1.7) respectively. Thus, the T1425M and I1426D mutations decreased the IC 50 by 16-fold and 5-fold, respectively, and CHTX (2) exhibited a comparable affinity for Na v 1.7 T1425M and Na v 1.3. An extra glycine unit connected to C11 in CHTX (2) was speculated to be responsible for the difference in mode of action between TTX (1) and CHTX (2). However, when the dose-responses of TTX (1, Supporting Information Figure  S5 ) and CHTX (2, Supporting Information Figure S6 ) were drawn at different membrane potentials and superimposed, it was shown to be less likely that TTX (1) and CHTX (2) exhibit voltage-dependent blocks. Furthermore, use-dependent blocks of Na v 1.3 and Na v 1.7 by TTX (1, Supporting Information Figure S7 ) and CHTX (2, Supporting Information Figure S8) were not observed.
Molecular modelling of TTX (1) and CHTX (2) was then performed using Spartan'14 (Supporting Information Figure S9 ). Their tricyclic scaffolds were almost superimposed, but there were differences in the side chain connected to C11. The dihedral angle of HOÀC6ÀC11ÀOH was À49.9°in TTX (1) and 41.8°in CHTX (2). In contrast, the dihedral angle of HOÀC6ÀC11ÀC12 in CHTX (2) was Figure 3 Inhibitory effects of CHTX (2) on Na v 1.1-Na v 1.7 expressed in HEK293T cells. The sodium currents in (A) Na v 1.1, (B) Na v 1.2, (C) Na v 1.3, (D) Na v 1.4, (E) Na v 1.5, (F) Na v 1.6 and (G) Na v 1.7 were recorded in the absence (black line) and presence (red line) of CHTX (2). The CHTX concentration was 30 nM in (AÀD, F, G) and 100 nM in (E). (H) The dose-dependent inhibitory effects of CHTX (2) on Na v 1.1, Na v 1.2, Na v 1.3, Na v 1.4, Na v 1.5, Na v 1.6 and Na v 1.7 are shown.
À82.5°. In addition, the distance between C6ÀOH and C12ÀO, C4ÀOH and C11ÀOH and C11ÀOH and C12ÀNH 2 were 1.7, 5.3 and 3.0 Å respectively. This indicated the existence of an intramolecular hydrogen bond between C6ÀOH and the carboxyl functionality in CHTX (2), which directed C11ÀOH and/or C12-NH 2 to the same spatial area where C4ÀOH was directed.
Discussion
In the present study, the inhibitory effects of the various TTX analogues (2-12) against each VSSC subtype were investigated for the first time to elucidate the structure-activity relationship between TTX (1) and VSSCs. The results show that the subtypes tested are largely insensitive to 8-deoxyTTX (3), 5-deoxyTTX (7), 5,11-dideoxyTTX (8) and 5, 6, at 300 nM (Supporting Information Table  S1 ). The IC 50 values determined in the present study for 5-deoxyTTX (7), 5, 6, were comparable to those determined in cell-based assays (Satake et al., 2014) . Most importantly, 5-deoxyTTX (7), 5, 6, lack the 10,7-hemilactal scaffold (Figure 1 ), which appears to be necessary to achieve high affinity for VSSCs. The significance of the hydroxy functionality of 4-OH, 6-OH, 8-OH and 11-OH in TTX (1) for achieving high affinity to VSSCs was reported by Yotsu-Yamashita et al. (Choudhary et al., 2003; Yotsu-Yamashita et al., 2003; Kudo et al., 2014; Saruhashi et al., 2016) and proposed in modelling studies (Lipkind and Fozzard, 1994; Choudhary et al., 2003; Tikhonov and Zhorov, 2005) . In addition, the present study investigated the blocking activity of VSSCs by 8-deoxyTTX (3), a synthetic analogue of TTX (1) that has not yet been identified from natural sources, in whole-cell patch-clamp recordings and emphasizes the importance of hydroxyl functionality in the high-affinity binding of TTX (1).
We were unable to reproduce the subtype-specific action of 4,9-anhydroTTX (4) (Rosker et al., 2007) . We verified the purity of synthetic 4,9-anhydroTTX (4) via NMR (Ohyabu et al., 2003; Nishikawa et al., 2004; Urabe et al., 2006) and used it to treat HEK293T cells expressing a single VSSC subtype; however, we observed that the working solution containing 100 nM 4,9-anhydroTTX (4) caused inhibition of Na v 1.6 (Supporting Information Figure S4 ) when it was stored for half a year, implying that the production of TTX (1) and 4-epiTTX occurred, probably attributable to an equilibrium between TTX (1), 4-epiTTX and 4,9-anhydroTTX (4), which may not support Rosker's results. Indeed, 300 nM 4,9-anhydroTTX (4) preferentially inhibited Na v 1.6 over that of Na v 1.4 and Na v 1.5 (Supporting Information Table S1 ). Because the voltage-dependent block of Na v 1.6 by 4,9-anhydroTTX (4) was assumed from the previous studies (Hargus et al., 2013; Rogers et al., 2016) , optimization of the Figure 4 An evaluation of the molecular determinants for the reduced binding of CHTX (2) to Na v 1.7. (A) An alignment of the Na v sequences at the TTXbinding sites from domains I to IV; the letters represent the amino acid residues. The numbers 379, 937, 1418 and 1710 indicated above the first residue in each domain, and 388, 946, 1427 and 1719 above the last residue in each domain are based on those in Na v 1.2. The letters in the grey background are the aspartate-glutamate-lysine-alanine (DEKA) residues important for ion selectivity, and the white letters 'C' and 'S' in the grey background indicate the residue responsible for the reduced binding of TTX (1). The white letters 'T' and 'I' in the black background represent the key residues for the reduced binding of CHTX (2) identified in the present study. (B) The dose-dependent inhibition of Na v 1.3, Na v 1.7, Na v 1.7 T1425M and Na v 1.7 I1426D by CHTX (2). The dose-response curves for Na v 1.3 and Na v 1.7 were identical to those in Figure 3H .
recording conditions might be able to restore the marked action of 4,9-anhydroTTX (4).
Herein, we present the first report regarding the inhibitory effects of CHTX (2) on Na v 1.1-Na v 1.7. The IC 50 values of CHTX (2) (Table 1) appear to be related to the halfactivation and/or inactivation potential of Na v 1.1-Na v 1.7 (Supporting Information Figure S3C ), although neither CHTX (2, Supporting Information Figure S6 ) nor TTX (1, Supporting Information Figure S5 ) exhibited a voltagedependent action. Use-dependent blocks of VSSCs have been characterized as a mode of action of TTX (1) (Boccaccio et al., 1999) . Many studies have assessed use-dependent blocks of VSSCs by TTX (1) with longer repetitive depolarization pulses than those used in the present study. As such, the present study applied a duration of 2 ms to the repetitive depolarization pulses and could not confirm use-dependent blocks by TTX (1) and CHTX (2). Indeed, use-dependent blocks of VSSCs by lidocaine, a local anaesthetic, depended on the duration period for the repetitive depolarization pulses (Nuss et al., 1995) , indicating that binding of a ligand to the inactivated state of VSSCs could induce use-dependent blocks. Thus, use-dependent blocks of the VSSCs by TTX (1) require conditions that facilitate the binding of TTX (1) to the inactivated state of VSSCs, although TTX (1) and CHTX (2) did not apparently affect VSSC inactivation when their steady-state VSSC blocks were being assessed (Figures 2  and 3 ). Further investigations are necessary to clarify the differences in mode of action between TTX (1) and CHTX (2).
We attributed the specific reduction of CHTX (2) binding to Na v 1.7 to Thr 1425 and Ile 1426 ( Figure 4A ), which are located at the outer vestibule of domain III of the VSSC, where Trp 1424 was predicted to contact C4ÀOH (Tikhonov and Zhorov, 2005) . We identified differences between TTX (1) and CHTX (2) by means of molecular modelling on the side chains connected at C11 (Supporting Information Figure S9 ). The small dihedral angle of HOÀC6ÀC11ÀOH in TTX (1) explains the interaction between these two hydroxyl functionalities and Asp 1717 in domain IV of the VSSC (Lipkind and Fozzard, 1994; Tikhonov and Zhorov, 2005 ). In contrast, an intramolecular hydrogen bond between C6ÀOH and the carboxyl functionality in CHTX (2), as addressed by Yotsu et al. (1990) (Supporting Information Figure S9 ), indicates a loss of the hydrogen bond between C11ÀOH and Asp 1717 (Choudhary et al., 2003) , which explains the finding that CHTX (2) binding affinities for each TTX-sensitive VSSC subtype were one order of magnitude weaker than those of TTX (1) These two consecutive amino acid residues are the key amino acid residues for STX (Walker et al., 2012) . The rodent Na v 1.4 has Met 1425 and Asp 1426 at these positions and shows a high affinity for STX, with an IC 50 value of 2.8 ± 0.1 nM, whereas mammalian Na v 1.7 has Thr 1425 and Ile 1426 at those positions and has a low affinity for STX (IC 50 = 702 ± 53 nM). The mammalian Na v 1.7 mutant carrying the T1425M and I1426D mutations had a 305-fold increase in binding affinity for STX (IC 50 = 2.3 ± 0.2 nM), which was almost identical to the IC 50 value for rodent Na v 1.4. We therefore propose that CHTX (2) was embedded in the binding pocket in a similar manner to that of STX (Walker et al., 2012) , in which the bulky Thr residue repels CHTX (2) and the Asp residue provides electrostatic stabilization with CHTX (2) (Walker et al., 2012) . The interactions between TTX (1)/STX and VSSC have been revealed experimentally or are based on models that were primarily constructed per the crystal structure of potassium channels. Thus, there is risk involved when applying CHTX (2) to the reported VSSC models to explain the high affinity binding of TTX (1). Furthermore, identification of mammalian VSSC crystal structures would be desirable to map the binding site of CHTX (2). Overall, we confirmed the molecular determinants in TTX (1) for generating high affinity binding to VSSCs. We also propose a similar mode of action for STX and CHTX (2), which results in the discrimination of human Na v 1.7 from other human TTX-sensitive VSSCs. The binding mode should be elucidated for CHTX (2), which would illustrate a novel model for binding TTX (1) to VSSCs. A thorough systemic method might be applicable to the search for subtype-specific blockers among TTX analogues for the development of therapeutic compounds.
presence (open circles) of 300 nM CHTX (2) with depolarizing stimuli at E) 1 Hz, F) 2 Hz, G) 5 Hz, and H) 10 Hz were investigated. Each symbol represents mean value ± SEM (n = 5). Figure S9 The stabilized conformations of TTX (1) and CHTX (2). The conformations were optimized with Spartan1 4 version 1.1.9. (Wavefunction, Inc., Irvine, CA, United States) using a conventional personal computer. Global calculations for equilibrium geometry at ground state were performed using Molecular Mechanics on Merck Molecular Force Field 94 (MMFF94).
Table S1 Inhibitory effect of TTX analogues of 3-12 on Na v 1.1-Na v 1.7. Each subtype from Na v 1.1 to Na v 1.7 was stimulated by each TTX derivative at 300 nM. Exceptions were 30 μM of 5-deoxyTTX (7) against Na v 1.5, 3 μM of 5,11-dideoxyTTX (8) against Nav1.3, and 1 μM of 5,11-dideoxyTTX (8) against Nav1.5. The values in the table represent the inhibitory effect (%) of each compound on the designated Na v subtype. Each value was determined from three independent experiments except those with grey (two independent experiments) and ocher background (a single experiment).
